Regulators tentatively endorse patient preference approach
PREFER’s proposals have been described by the EMA as a “comprehensive reference document for planning and conducting patient preference studies’’.
Site Search
Site Search
Displaying results 21 - 30 of 893
Multiple important milestones advance Ebola vaccine regimen uptake
European marketing authorisation, WHO prequalification and an expert-backed recommendation mean the IMI-funded J&J vaccine is closer to widespread uptake to prevent future outbreaks.
Exploitation of project results
IMI project partners have a contractual obligation to ensure exploitation of their results for research use and/or direct exploitation either by themselves, e.g. for further research or for commercial or industrial exploitation in its own activities, or by other beneficiaries or ...
Researcher wins prestigious award for platform trial simulation study
EU-PEARL’s Elias Laurin Meyer was awarded Arthur-Linder-Prize for developing simulations that will help design platform trials, in which multiple therapies are tested at once.
Scientists discover a highly potent antibody against SARS-CoV-2
Researchers in Switzerland, working as part of the CARE consortium, have isolated a highly potent monoclonal antibody against SARS-CoV-2, one of the most powerful identified so far.
FACILITATE
Framework for clinical trial participants data reutilization for a fully transparent and ethical ecosystem
OPTIMA
Optimal treatment for patients with solid tumours in Europe through artificial intelligence
Screen4Care
Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies
BEAMER
Behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare
Surge vaccine production principles now written into EU law
ZAPI’s work can help dramatically speed up the development and approval of new shots for COVID strains, but also flu, malaria and other infectious diseases
